Merck & Co., Inc. (NYSE:MRK) is included among the 16 Best Dividend Stocks with Rising Payouts. On February 13, Deutsche Bank ...

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.

Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios. Merck stands out for its leadership in oncology, complemented by strong positions in ...

Merck (MRK) pharma stock has been on a climb for some time now but has recently stalled near a familiar breakdown zone ...

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile ...

Merck & Co., Inc. is a global biopharmaceutical enterprise engaged in discovery, development, manufacturing, and commercialization of prescription medicines, vaccines, biologic therapies, and animal ...

Merck (MRK) reports positive Phase 3 SMART trial results for ENFLONSIA in high-risk infants/children vs RSV, with consistent safety and dosing—read ...

Merck is scheduled to release its earnings report on Thursday, April 24, 2025. Historical data suggests that MRK stock often reacts negatively to such announcements. Over the past five years, the ...

Merck & Company Inc. (NYSE:MRK) operates as a diversified biopharmaceutical organisation with activities spanning medicines, ...

Merck (MRK)’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence. The factors behind this ...

Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total ...